Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492877 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 381
- Enrollment target
NCT05492877 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 381 participants.
The verdict
NCT05492877, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 381 participants
- Enrollment target
Study Summary
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
Interventions
- OTHER Placebo
- DRUG Mitiperstat (AZD4831)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05492877
The ClinicalTrials.gov registry entry for NCT05492877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05492877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05492877 about?
NCT05492877 is a clinical study titled "An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.". This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
What is the current status of trial NCT05492877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 381 participants. The study started on 2022-11-14. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT05492877?
The interventions under investigation include: Placebo (OTHER), Mitiperstat (AZD4831) (DRUG).
Who is sponsoring clinical trial NCT05492877?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.